Provided by Tiger Trade Technology Pte. Ltd.

MannKind

2.28
-0.0200-0.87%
Post-market: 2.290.0065+0.29%19:59 EDT
Volume:5.60M
Turnover:12.76M
Market Cap:700.12M
PE:114.00
High:2.32
Open:2.27
Low:2.23
Close:2.30
52wk High:6.51
52wk Low:2.23
Shares:307.07M
Float Shares:300.98M
Volume Ratio:0.53
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0200
EPS(LYR):0.0200
ROE:32.74%
ROA:4.91%
PB:-13.72
PE(LYR):114.00

Loading ...

Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating

MT Newswires Live
·
Nov 11, 2025

MannKind’s Strategic Advancements and Product Potential Justify Buy Rating Despite MNKD-101 Discontinuation

TIPRANKS
·
Nov 11, 2025

REFILE-BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Tower Semiconductor, GlobalFoundries

Reuters
·
Nov 11, 2025

H.C. Wainwright remains bullish on MannKind despite disappointing MNKD-101 news

TIPRANKS
·
Nov 11, 2025

MannKind’s Resilience and Growth Potential: A Buy Rating Amid Setbacks and Opportunities

TIPRANKS
·
Nov 11, 2025

MannKind Corp : Leerink Partners Cuts Target Price to $7 From $9

THOMSON REUTERS
·
Nov 10, 2025

MannKind Shares Fall 3.3% After Co to Discontinue Late-Stage Trial of Lung Disease Treatment

THOMSON REUTERS
·
Nov 10, 2025

MannKind Discontinues Phase 3 Trial of Nebulized Clofazimine to Treat Lung Disease

MT Newswires Live
·
Nov 10, 2025

MannKind Shares Down After Lung Disease Drug Trial Discontinued

Dow Jones
·
Nov 10, 2025

MannKind provides update on Phase 3 ICoN-1 trial of nebulized clofazimine

TIPRANKS
·
Nov 10, 2025

MannKind Shares Fall 5.7% Premarket After Co to Discontinue Phase 3 Clinical Trial of Lung Disease Treatment

THOMSON REUTERS
·
Nov 10, 2025

Stock Track | MannKind Plunges 6.75% Pre-market as Company Discontinues Key Phase 3 Trial

Stock Track
·
Nov 10, 2025

Stock Track | MannKind Shares Plummet 6.75% Pre-market on Discontinuation of Key Phase 3 Trial

Stock Track
·
Nov 10, 2025

MannKind Corp - Mnkd-102 Development Remains Under Consideration

THOMSON REUTERS
·
Nov 10, 2025

MannKind: No Conversions Observed in Phase 3 ICON-1 Trial, Prompting Concerns Regarding Likelihood of Achieving Study's Key Primary Endpoint

THOMSON REUTERS
·
Nov 10, 2025

MannKind Provides Update on Phase 3 ICON-1 Trial of Nebulized Clofazimine for Ntm Lung Disease

THOMSON REUTERS
·
Nov 10, 2025

MannKind Corp - Independent Dsmb Agrees to Discontinue Trial Due to Futility

THOMSON REUTERS
·
Nov 10, 2025

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

GlobeNewswire
·
Nov 06, 2025

MannKind’s Record Q3 2025 Earnings and Strategic Moves

TIPRANKS
·
Nov 06, 2025

Update: MannKind Shares Rise After Q3 Beat

MT Newswires Live
·
Nov 06, 2025